Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082381 · ClinicalTrials.gov registry record · Phase 3
Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 551
- Enrollment target
NCT00082381: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00082381 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 551 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00082381, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 551 participants
- Enrollment target
Study Summary
This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).
Primary Outcome
Change in HbA1c from baseline to week 26
Interventions
- DRUG Insulin glargine
- DRUG Exenatide (AC2993)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 551 participants |
| Start Date | 2003-06 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
What the finished NCT00082381 record still lists
NCT00082381 is an interventional study that assigns participants to a tested intervention. The registered 551 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 2 interventions - of which Insulin glargine is the first listed.
NCT00082381 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00082381 about?
NCT00082381 is a clinical study titled "Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin". This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).
What is the current status of trial NCT00082381?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 551 participants. The study started on 2003-06. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00082381?
The interventions under investigation include: Insulin glargine (DRUG), Exenatide (AC2993) (DRUG).
Who is sponsoring clinical trial NCT00082381?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00082381's enrollment target sits among peer trials
551 680th of 2000 higher than 1,321 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06217809 · 552 participants · NA
EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.
- NCT07146022 · 552 participants · Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia